Mycobacterium marinum : An Increasingly Common Opportunistic Infection in Patients on Infl iximab
Jason Ferreira , MD 1 , Jared Grochowsky , MD To the Editor : Th e introduction of infl iximab over a decade ago revolutionized the treatment of Crohn ' s disease, but as experience with the drug has grown, physicians have observed an increased risk of serious and opportunistic infections associated with its use. Th e following case describes the course of a Crohn ' s patient on infl iximab, who developed a cutaneous Mycobacterium marinum infection.
A 50-year-old male with ileocolonic fi stulizing Crohn ' s disease, diagnosed in his early 20s, whose disease course has been complicated by multiple abdominal surgeries and poor adherence with oral immunosuppressives, presented to his primary care physician for evaluation of right hand pain, swelling, and purulent discharge, shortly aft er receiving his third infl iximab infusion. He did not report any fevers or chills, but was noted to have a warm, indurated, erythematous lesion on his right palm, with evidence of erythematous streaking to his elbow concerning for lymphangitic spread. He is an avid gardener, owns a home saltwater aquarium, and recalled suff ering a puncture wound to his right hand a week before noticing the symptoms.
Shortly aft er receiving his fourth infl ixi mab dose, he was seen in the gastro enterology clinic for routine follow-up and was noted to have multiple indurated lesions on the thenar surface of his right palm with two subcutaneous nodules also seen on his right wrist and forearm, despite having completed a 10-day course of cephalexin. Further infl iximab therapy was held and he was referred to dermato logy where a culture and biopsy was performed to diff erentiate between M. marinum infection and sporotrichosis. He was started empirically on minocycline and his physical exam remained unchanged upon follow-up in the infectious disease clinic 1 week later, at which point his antibiotic regimen was changed to ethambutol and clarithromycin with results of his culture still pending.
Six weeks from his original dermatology visit, the culture returned positive for M. marinum and his antibiotic regimen was continued. It took 3 months before the infection began to recede and he selfdiscontinued the antibiotics aft er a total of 7 months of treatment, despite having persistent skin lesions.
Th is case adds to the growing body of literature describing increased opportunistic infections with anti-tumor necrosis factor (TNF) therapy, including atypical mycobacterial infections. As TNF-α has an integral part in the pathway leading to granuloma formation and maintenance ( 1 ), blockade of this factor would logically lead to an increased risk of mycobacterial infections. In fact, post-marketing Food and Drug Administration surveillance through January of 2007 has noted 239 atypical mycobacterial infections in patients taking anti-TNF-α biological therapy ( 2 ) , and 12 diff erent species of mycobacterium have been implicated ( 3 ).
Most M. marinum infections stem from aquarium exposure, fi sh-or shellfi shassociated injuries, and injuries associated with salt or brackish water ( 4 ) . Atypical mycobacterial infections in immunosuppressed patients on anti-TNF therapy may show delayed response to therapy and portend serious morbidity. In addition to routine screening with hepatitis serologies, PPD, and close followup with the prescribing physician, a complete social history should be obtained looking for any red fl ags that would predispose a patient to infectious complications. To the Editor : Tuberculosis (TB) of the stomach is uncommon, and accounts for 0.5 -3 % of all cases of gastrointestinal TB ( 1 ). Mostly it is secondary to pulmonary TB. Primary and isolated gastric TB is rare ( 2 ) and has been reported sporadically ( 3, 4 ) . Various reported presentations include gastric outlet obstruction, upper gastrointestinal bleeding, or pseudotumor ( 2 ). However, primary gastric TB mimicking gastrointestinal stromal tumor (GIST) has not been reported so far.
Primary Gastric
A 28-year-old man presented with mild epigastric pain, intermittent non-bilious vomiting, and dyspepsia for 2 years with 4 kg weight loss with no response to antisecretory medications. Th ere was no history of anorexia, fever, or gastrointestinal bleeding. Th ere has been no other relevant medical or surgical past history. Physical examination was non-contributory. Blood investigations including hemogram, liver, and renal function tests were within normal limits. Chest X-ray did not reveal any signifi cant fi ndings.
Esophagogastroduodenoscopy was performed, which showed a small sessile polypoidal submucosal lesion in the gastric antrum with normal overlying mucosa ( Figure 1a ) . Th e remaining stomach and the duodenum were found to be normal. On endoscopic ultrasonography (EUS), the lesion appeared as a round, well-defi ned, uniformly hypoechoic lesion measuring 1.5 cm × 1.5 cm occupying the fourth layer of the gastric wall ( Figure 1b ) with no signifi cant perigastric lymphadenopathy. Computed tomography also revealed a well-defi ned solid, hypo dense lesion in the antral wall with no other signifi cant fi ndings, e.g., abdominal lymphadenopathy or ascites ( Supplementary Figure 1 online) .
Given the above fi ndings, a provisional diagnosis of GIST was proposed, and the patient underwent laparoscopic wedge resection of the tumor. Intraoperative endoscopy was performed to assist in localizing the lesion that was present on the posterior antral wall along the greater curvature. No signifi cant lymphadenopathy was found intraoperatively.
Gross examination revealed an ~ 2 cm × 2 cm intramural cystic lesion fi lled with thick pus with indurated wall ( Supplementary  Figure 2 ) . No organism was demonstrated on Gram ' s staining or Ziehl -Neelsen staining of the pus that was found to be sterile on culture. Histopathological examination, however, showed chronic infl ammatory infi ltrates with epithelioid cell granulomas a b 
